Cancer Therapy
Pharma company reports 2004 financial results, remains optimistic
Published in Medical Letter on the CDC and FDA, September 19th, 2004
For the fourth quarter of 2004, Pharmacyclics recorded a net loss of $7.3 million, or $0.38 per share, compared to a net loss of $7.5 million, or $0.46 per share, for the fourth quarter of 2003.
Research and development expenses remained constant at $6.2 million for the fourth quarter 2004 when compared to the fourth quarter of 2003, as the company continued enrolling patients in a randomized pivotal Phase 3 trial evaluating the efficacy and safety of Xcytrin (motexafin gadolinium) Injection for the treatment of brain metastases...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Antimicrobial Resistance
Mutation spectra provide insights into quinolone resistance in Salmonella - Diabetes
Tools available to promote diabetes prevention - Environmental Health
Perfluorinated organic acids and amides in human serum and milk measured - Food-Borne Illness
Modifications of Charm II assay for chloramphenicol in honey described - Lymphoma Therapy
Rac1 inhibits apoptosis in human lymphoma cells - Accreditation
Overhaul urged for accreditation of medical labs - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
